Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 415Cytarabine 337fludarabine phosphate 231Rituximab 206Methotrexate 199fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 113Melphalan 110Dexamethasone 110Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Daunorubicin 91Antilymphocyte Serum 91Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 71Prednisone 69Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × CX 3543 × Other hematologic neoplasm × Clear all
NCT00485966 2008-11-05

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Cylene Pharmaceuticals

Phase 2 Withdrawn
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡